OncoResponse is using clinically validated platform technology to rapidly screen and discover therapeutically relevant antibodies from patients with elite response to disease. Those cancer patients with exceptional reactivity to immunotherapy are being used to identify potential targets for novel therapeutic development in the areas of melanoma, non-small cell lung cancer (NSCLC), prostate cancer, gastric cancer, and chronic myeloid leukemia (CML), with additional programs under development. For more information, please visit our partnering page.